The  ||| S:0 E:4 ||| DT
poor  ||| S:4 E:9 ||| JJ
prognosis  ||| S:9 E:19 ||| NN
factors  ||| S:19 E:27 ||| NNS
in  ||| S:27 E:30 ||| IN
G2  ||| S:30 E:33 ||| CD
neuroendocrine  ||| S:33 E:48 ||| JJ
tumor  ||| S:48 E:54 ||| NN
The  ||| S:54 E:58 ||| DT
G2  ||| S:58 E:61 ||| FW
neuroendocrine  ||| S:61 E:76 ||| FW
tumors  ||| S:76 E:83 ||| FW
( ||| S:83 E:84 ||| -LRB-
NET ||| S:84 E:87 ||| NNP
)  ||| S:87 E:89 ||| -RRB-
or  ||| S:89 E:92 ||| CC
well-differentiated  ||| S:92 E:112 ||| JJ
neuroendocrine  ||| S:112 E:127 ||| JJ
carcinomas  ||| S:127 E:138 ||| NNS
( ||| S:138 E:139 ||| -LRB-
2010  ||| S:139 E:144 ||| CD
WHO  ||| S:144 E:148 ||| WP
Classification  ||| S:148 E:163 ||| NNP
of  ||| S:163 E:166 ||| IN
Tumours  ||| S:166 E:174 ||| NNP
of  ||| S:174 E:177 ||| IN
the  ||| S:177 E:181 ||| DT
Digestive  ||| S:181 E:191 ||| NNP
System ||| S:191 E:197 ||| NNP
)  ||| S:197 E:199 ||| -RRB-
embrace  ||| S:199 E:207 ||| VB
different  ||| S:207 E:217 ||| JJ
types  ||| S:217 E:223 ||| NNS
of  ||| S:223 E:226 ||| IN
evolution  ||| S:226 E:236 ||| NN
despite  ||| S:236 E:244 ||| IN
the  ||| S:244 E:248 ||| DT
fact  ||| S:248 E:253 ||| NN
that  ||| S:253 E:258 ||| IN
they  ||| S:258 E:263 ||| PRP
actually  ||| S:263 E:272 ||| RB
are  ||| S:272 E:276 ||| VBP
included  ||| S:276 E:285 ||| VBN
in  ||| S:285 E:288 ||| IN
the  ||| S:288 E:292 ||| DT
same  ||| S:292 E:297 ||| JJ
group  ||| S:297 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
prognosis  ||| S:306 E:316 ||| VBG
based  ||| S:316 E:322 ||| VBN
on  ||| S:322 E:325 ||| IN
mitotic  ||| S:325 E:333 ||| JJ
count  ||| S:333 E:339 ||| NN
and  ||| S:339 E:343 ||| CC
the  ||| S:343 E:347 ||| DT
Ki-67  ||| S:347 E:353 ||| JJ
proliferation  ||| S:353 E:367 ||| NN
index ||| S:367 E:372 ||| NN
.  ||| S:372 E:374 ||| .
We  ||| S:374 E:377 ||| PRP
studied  ||| S:377 E:385 ||| VBD
the  ||| S:385 E:389 ||| DT
pathological  ||| S:389 E:402 ||| NN
and  ||| S:402 E:406 ||| CC
clinical  ||| S:406 E:415 ||| JJ
aspects  ||| S:415 E:423 ||| NNS
in  ||| S:423 E:426 ||| IN
patients  ||| S:426 E:435 ||| NNS
with  ||| S:435 E:440 ||| IN
G2  ||| S:440 E:443 ||| NNP
NET ||| S:443 E:446 ||| NNP
.  ||| S:446 E:448 ||| .
This  ||| S:448 E:453 ||| DT
is  ||| S:453 E:456 ||| VBZ
a  ||| S:456 E:458 ||| DT
retrospective  ||| S:458 E:472 ||| JJ
pilot  ||| S:472 E:478 ||| NN
observational  ||| S:478 E:492 ||| NN
study  ||| S:492 E:498 ||| NN
in  ||| S:498 E:501 ||| IN
patients  ||| S:501 E:510 ||| NNS
admitted  ||| S:510 E:519 ||| VBN
between  ||| S:519 E:527 ||| IN
January  ||| S:527 E:535 ||| NNP
2008  ||| S:535 E:540 ||| CD
and  ||| S:540 E:544 ||| CC
January  ||| S:544 E:552 ||| NNP
2013  ||| S:552 E:557 ||| CD
in  ||| S:557 E:560 ||| IN
Constantin  ||| S:560 E:571 ||| NNP
I.  ||| S:571 E:574 ||| NNP
Parhon  ||| S:574 E:581 ||| NNP
National  ||| S:581 E:590 ||| NNP
Institute  ||| S:590 E:600 ||| NNP
of  ||| S:600 E:603 ||| IN
Endocrinology ||| S:603 E:616 ||| NNP
,  ||| S:616 E:618 ||| ,
Bucharest ||| S:618 E:627 ||| NNP
,  ||| S:627 E:629 ||| ,
Romania ||| S:629 E:636 ||| NNP
.  ||| S:636 E:638 ||| .
They  ||| S:638 E:643 ||| PRP
were  ||| S:643 E:648 ||| VBD
evaluated  ||| S:648 E:658 ||| VBN
based  ||| S:658 E:664 ||| VBN
on  ||| S:664 E:667 ||| IN
the  ||| S:667 E:671 ||| DT
pathological  ||| S:671 E:684 ||| JJ
report ||| S:684 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
imagistic  ||| S:692 E:702 ||| JJ
scan ||| S:702 E:706 ||| NN
,  ||| S:706 E:708 ||| ,
and  ||| S:708 E:712 ||| CC
neuroendocrine  ||| S:712 E:727 ||| JJ
markers ||| S:727 E:734 ||| NN
.  ||| S:734 E:736 ||| .
Nine  ||| S:736 E:741 ||| CD
patients  ||| S:741 E:750 ||| NNS
( ||| S:750 E:751 ||| -LRB-
female ||| S:751 E:757 ||| JJ
/ ||| S:757 E:758 ||| CD
male  ||| S:758 E:763 ||| JJ
ratio ||| S:763 E:768 ||| NN
:  ||| S:768 E:770 ||| :
5 ||| S:770 E:771 ||| CD
/ ||| S:771 E:772 ||| CD
4 ||| S:772 E:773 ||| CD
)  ||| S:773 E:775 ||| -RRB-
with  ||| S:775 E:780 ||| IN
G2  ||| S:780 E:783 ||| NNP
NET  ||| S:783 E:787 ||| NNP
were  ||| S:787 E:792 ||| VBD
included  ||| S:792 E:801 ||| VBN
( ||| S:801 E:802 ||| -LRB-
mean  ||| S:802 E:807 ||| JJ
age  ||| S:807 E:811 ||| NN
at  ||| S:811 E:814 ||| IN
diagnosis  ||| S:814 E:824 ||| CD
54.11  ||| S:824 E:830 ||| CD
years ||| S:830 E:835 ||| NNS
) ||| S:835 E:836 ||| -RRB-
.  ||| S:836 E:838 ||| .
Surgery  ||| S:838 E:846 ||| NN
was  ||| S:846 E:850 ||| VBD
performed  ||| S:850 E:860 ||| VBN
in  ||| S:860 E:863 ||| IN
66.66 ||| S:863 E:868 ||| CD
%  ||| S:868 E:870 ||| NN
of  ||| S:870 E:873 ||| IN
cases.  ||| S:873 E:880 ||| CD
44.44 ||| S:880 E:885 ||| CD
%  ||| S:885 E:887 ||| NN
of  ||| S:887 E:890 ||| IN
tumors  ||| S:890 E:897 ||| NNS
had  ||| S:897 E:901 ||| VBD
unknown  ||| S:901 E:909 ||| JJ
origin.  ||| S:909 E:917 ||| CD
22.22 ||| S:917 E:922 ||| CD
%  ||| S:922 E:924 ||| NN
of  ||| S:924 E:927 ||| IN
patients  ||| S:927 E:936 ||| NNS
had  ||| S:936 E:940 ||| VBD
negative  ||| S:940 E:949 ||| JJ
immunostain  ||| S:949 E:961 ||| NN
for  ||| S:961 E:965 ||| IN
chromogranin  ||| S:965 E:978 ||| JJ
A.  ||| S:978 E:981 ||| NNP
Synaptophysin  ||| S:981 E:995 ||| NNP
was  ||| S:995 E:999 ||| VBD
positive  ||| S:999 E:1008 ||| JJ
in  ||| S:1008 E:1011 ||| IN
all  ||| S:1011 E:1015 ||| DT
cases ||| S:1015 E:1020 ||| NNS
.  ||| S:1020 E:1022 ||| .
Neuronal  ||| S:1022 E:1031 ||| JJ
specific  ||| S:1031 E:1040 ||| JJ
enolase  ||| S:1040 E:1048 ||| NNS
( ||| S:1048 E:1049 ||| -LRB-
NSE ||| S:1049 E:1052 ||| NNP
)  ||| S:1052 E:1054 ||| -RRB-
was  ||| S:1054 E:1058 ||| VBD
performed  ||| S:1058 E:1068 ||| VBN
in  ||| S:1068 E:1071 ||| IN
44.44 ||| S:1071 E:1076 ||| CD
%  ||| S:1076 E:1078 ||| NN
of  ||| S:1078 E:1081 ||| IN
cases  ||| S:1081 E:1087 ||| NNS
and  ||| S:1087 E:1091 ||| CC
it  ||| S:1091 E:1094 ||| PRP
was  ||| S:1094 E:1098 ||| VBD
positive  ||| S:1098 E:1107 ||| JJ
in  ||| S:1107 E:1110 ||| IN
all  ||| S:1110 E:1114 ||| PDT
these  ||| S:1114 E:1120 ||| DT
situations.  ||| S:1120 E:1132 ||| CD
88.88 ||| S:1132 E:1137 ||| CD
%  ||| S:1137 E:1139 ||| NN
of  ||| S:1139 E:1142 ||| IN
patients  ||| S:1142 E:1151 ||| NNS
had  ||| S:1151 E:1155 ||| VBD
high  ||| S:1155 E:1160 ||| JJ
neuroendocrine  ||| S:1160 E:1175 ||| JJ
markers ||| S:1175 E:1182 ||| NN
.  ||| S:1182 E:1184 ||| .
Multiple  ||| S:1184 E:1193 ||| JJ
tumors  ||| S:1193 E:1200 ||| NNS
were  ||| S:1200 E:1205 ||| VBD
found  ||| S:1205 E:1211 ||| VBN
in  ||| S:1211 E:1214 ||| IN
two  ||| S:1214 E:1218 ||| CD
cases  ||| S:1218 E:1224 ||| NNS
( ||| S:1224 E:1225 ||| -LRB-
follicular  ||| S:1225 E:1236 ||| FW
thyroid  ||| S:1236 E:1244 ||| FW
adenoma ||| S:1244 E:1251 ||| FW
,  ||| S:1251 E:1253 ||| ,
and  ||| S:1253 E:1257 ||| CC
a  ||| S:1257 E:1259 ||| DT
carcinoma  ||| S:1259 E:1269 ||| NN
of  ||| S:1269 E:1272 ||| IN
the  ||| S:1272 E:1276 ||| DT
port  ||| S:1276 E:1281 ||| JJ
vein ||| S:1281 E:1285 ||| NN
,  ||| S:1285 E:1287 ||| ,
respective  ||| S:1287 E:1298 ||| FW
bilaterally  ||| S:1298 E:1310 ||| FW
pheochromocytomas ||| S:1310 E:1327 ||| FW
) ||| S:1327 E:1328 ||| -RRB-
.  ||| S:1328 E:1330 ||| .
The  ||| S:1330 E:1334 ||| DT
youngest  ||| S:1334 E:1343 ||| JJS
patient  ||| S:1343 E:1351 ||| NN
( ||| S:1351 E:1352 ||| -LRB-
39-year-old ||| S:1352 E:1363 ||| NNP
)  ||| S:1363 E:1365 ||| -RRB-
had  ||| S:1365 E:1369 ||| VBD
atypical  ||| S:1369 E:1378 ||| JJ
onset  ||| S:1378 E:1384 ||| NN
with  ||| S:1384 E:1389 ||| IN
bilateral  ||| S:1389 E:1399 ||| JJ
adrenal  ||| S:1399 E:1407 ||| JJ
tumors  ||| S:1407 E:1414 ||| NNS
( ||| S:1414 E:1415 ||| -LRB-
positive  ||| S:1415 E:1424 ||| JJ
for  ||| S:1424 E:1428 ||| IN
CHROMO ||| S:1428 E:1434 ||| NNP
,  ||| S:1434 E:1436 ||| ,
EMA ||| S:1436 E:1439 ||| NNP
,  ||| S:1439 E:1441 ||| ,
CK-19 ||| S:1441 E:1446 ||| NNP
,  ||| S:1446 E:1448 ||| ,
CK-20 ||| S:1448 E:1453 ||| NNP
,  ||| S:1453 E:1455 ||| ,
negative  ||| S:1455 E:1464 ||| JJ
for  ||| S:1464 E:1468 ||| IN
SOMATO ||| S:1468 E:1474 ||| NNP
,  ||| S:1474 E:1476 ||| ,
CK-7 ||| S:1476 E:1480 ||| NNP
,  ||| S:1480 E:1482 ||| ,
S-100 ||| S:1482 E:1487 ||| NNP
,  ||| S:1487 E:1489 ||| ,
glucagon ||| S:1489 E:1497 ||| NN
,  ||| S:1497 E:1499 ||| ,
CD57 ||| S:1499 E:1503 ||| NNP
,  ||| S:1503 E:1505 ||| ,
and  ||| S:1505 E:1509 ||| CC
a  ||| S:1509 E:1511 ||| DT
Ki-67  ||| S:1511 E:1517 ||| NN
of  ||| S:1517 E:1520 ||| IN
15 ||| S:1520 E:1522 ||| CD
% ||| S:1522 E:1523 ||| NN
) ||| S:1523 E:1524 ||| -RRB-
.  ||| S:1524 E:1526 ||| .
Death  ||| S:1526 E:1532 ||| NN
was  ||| S:1532 E:1536 ||| VBD
registered  ||| S:1536 E:1547 ||| VBN
in  ||| S:1547 E:1550 ||| IN
two  ||| S:1550 E:1554 ||| CD
cases ||| S:1554 E:1559 ||| NNS
,  ||| S:1559 E:1561 ||| ,
both  ||| S:1561 E:1566 ||| DT
with  ||| S:1566 E:1571 ||| IN
bone  ||| S:1571 E:1576 ||| NN
metastases ||| S:1576 E:1586 ||| NN
.  ||| S:1586 E:1588 ||| .
Some  ||| S:1588 E:1593 ||| DT
poor  ||| S:1593 E:1598 ||| JJ
prognosis  ||| S:1598 E:1608 ||| NN
factors  ||| S:1608 E:1616 ||| NNS
may  ||| S:1616 E:1620 ||| MD
be  ||| S:1620 E:1623 ||| VB
taken  ||| S:1623 E:1629 ||| VBN
into  ||| S:1629 E:1634 ||| IN
account  ||| S:1634 E:1642 ||| NN
as  ||| S:1642 E:1645 ||| IN
lack  ||| S:1645 E:1650 ||| NN
of  ||| S:1650 E:1653 ||| IN
CHROMO  ||| S:1653 E:1660 ||| NNP
immunostain ||| S:1660 E:1671 ||| NN
,  ||| S:1671 E:1673 ||| ,
young  ||| S:1673 E:1679 ||| JJ
age  ||| S:1679 E:1683 ||| NN
at  ||| S:1683 E:1686 ||| IN
diagnosis ||| S:1686 E:1695 ||| NN
,  ||| S:1695 E:1697 ||| ,
genetic  ||| S:1697 E:1705 ||| JJ
background ||| S:1705 E:1715 ||| NN
,  ||| S:1715 E:1717 ||| ,
and  ||| S:1717 E:1721 ||| CC
lack  ||| S:1721 E:1726 ||| NN
of  ||| S:1726 E:1729 ||| IN
therapy  ||| S:1729 E:1737 ||| NN
options  ||| S:1737 E:1745 ||| NNS
as  ||| S:1745 E:1748 ||| IN
surgery ||| S:1748 E:1755 ||| NN
.  ||| S:1755 E:1757 ||| .
Larger  ||| S:1757 E:1764 ||| JJR
databases  ||| S:1764 E:1774 ||| NNS
will  ||| S:1774 E:1779 ||| MD
provide  ||| S:1779 E:1787 ||| VB
more  ||| S:1787 E:1792 ||| JJR
information ||| S:1792 E:1803 ||| NN
.  ||| S:1803 E:1805 ||| .
It  ||| S:1805 E:1808 ||| PRP
is  ||| S:1808 E:1811 ||| VBZ
possible  ||| S:1811 E:1820 ||| JJ
that  ||| S:1820 E:1825 ||| IN
the  ||| S:1825 E:1829 ||| DT
G2  ||| S:1829 E:1832 ||| NNP
NET  ||| S:1832 E:1836 ||| NNP
group  ||| S:1836 E:1842 ||| NN
of  ||| S:1842 E:1845 ||| IN
tumors  ||| S:1845 E:1852 ||| NNS
actually  ||| S:1852 E:1861 ||| RB
includes  ||| S:1861 E:1870 ||| VBZ
some  ||| S:1870 E:1875 ||| DT
different  ||| S:1875 E:1885 ||| JJ
subtypes  ||| S:1885 E:1894 ||| NN
or  ||| S:1894 E:1897 ||| CC
in  ||| S:1897 E:1900 ||| IN
fact ||| S:1900 E:1904 ||| NN
,  ||| S:1904 E:1906 ||| ,
a  ||| S:1906 E:1908 ||| DT
late  ||| S:1908 E:1913 ||| JJ
diagnosis  ||| S:1913 E:1923 ||| NN
of  ||| S:1923 E:1926 ||| IN
the  ||| S:1926 E:1930 ||| DT
tumor  ||| S:1930 E:1936 ||| NN
might  ||| S:1936 E:1942 ||| MD
be  ||| S:1942 E:1945 ||| VB
associated  ||| S:1945 E:1956 ||| VBN
with  ||| S:1956 E:1961 ||| IN
a  ||| S:1961 E:1963 ||| DT
poor  ||| S:1963 E:1968 ||| JJ
diagnosis ||| S:1968 E:1977 ||| NN
.  ||| S:1977 E:1979 ||| .
